Association Between Nuclear Expression of Retinoic Acid Receptor Alpha and Beta and Clinicopathological Features and Prognosis of Advanced Non-small Cell Lung Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2016 Jun 17

PMID 27306217

Citations 7

Authors

Sae Muniz-Hernandez

Sara Huerta-Yepez

Norma Hernandez-Pedro

Laura-Alejandra Ramirez-Tirado

Alejandro Aviles-Salas

Altagracia Maldonado

Daniel Hernandez-Cueto

Guillermina Baay-Guzman

Oscar Arrieta

Affiliations

Soon will be listed here.

Abstract

Background: Transcription factors such as retinoic acid receptor alpha (RARα) and beta (RARβ) and Yin Yang 1 (YY1) are associated with the progression of non-small cell lung cancer (NSCLC). In particular, a lack of RARβ expression is associated with NSCLC development. The aim of this study was to analyze the expression of RARα, RARβ and YY1 and their relationship with prognosis in patients with advanced NSCLC.

Methods: The expression of RARα, RARβ and YY1 was assessed by immunohistochemistry and quantitative computerized image software.

Results: Eighty-five patients treated with platinum-based chemotherapy were included in the analysis. The mean and standard deviation of the nuclear expression of RARα, RARβ and YY1 were 184.5 ± 124.4, 18 ± 27 and 16.6 ± 20.5, respectively. The nuclear expression of RARβ was associated with the nuclear expression of YY1 (R = 0.28; p value < 0.0001). Patients with high nuclear expression of YY1 were likely to be non-smokers (61.9 vs 40.5 %). Median progression-free survival (PFS) was 5.9 months (3.48-8.28). Low expression of RARα was independently associated with worse PFS following chemotherapy (10.3 vs 5.46 months p = 0.040). Median overall survival (OS) was 15.6 months (4.5-26.7), and lower nuclear expression of RARβ was independently associated with shorter OS (27.5 vs 8.7 months; p = 0.037).

Conclusion: Our study suggests that the loss of RARs is associated with a worse prognosis and these receptors could be a potential molecular target for NSCLC.

Citing Articles

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.

Omega-6 Polyunsaturated Fatty Acids Enhance Tumor Aggressiveness in Experimental Lung Cancer Model: Important Role of Oxylipins.

Montecillo-Aguado M, Tirado-Rodriguez B, Antonio-Andres G, Morales-Martinez M, Tong Z, Yang J Int J Mol Sci. 2022; 23(11).

PMID: 35682855 PMC: 9181584. DOI: 10.3390/ijms23116179.

Targeting Nuclear Receptors in Lung Cancer-Novel Therapeutic Prospects.

Gangwar S, Kumar A, Yap K, Jose S, Parama D, Sethi G Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631448 PMC: 9145966. DOI: 10.3390/ph15050624.

STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients.

Muniz-Hernandez S, Velazquez-Fernandez J, Diaz-Chavez J, Mondragon-Fonseca O, Mayen-Lobo Y, Ortega A Front Oncol. 2020; 10:579561.

PMID: 33324556 PMC: 7723324. DOI: 10.3389/fonc.2020.579561.

Aryl Hydrocarbon Receptor-Dependent inductions of omega-3 and omega-6 polyunsaturated fatty acid metabolism act inversely on tumor progression.

Huerta-Yepez S, Tirado-Rodriguez A, Montecillo-Aguado M, Yang J, Hammock B, Hankinson O Sci Rep. 2020; 10(1):7843.

PMID: 32398692 PMC: 7217871. DOI: 10.1038/s41598-020-64146-6.

References

Ishii H, Hulett M, Li J, Santiago F, Parish C, Khachigian L . Yin Yang-1 inhibits tumor cell growth and inhibits p21WAF1/Cip1 complex formation with cdk4 and cyclin D1. Int J Oncol. 2012; 40(5):1575-80. DOI: 10.3892/ijo.2012.1362. View

Tomizawa Y, Iijima H, Nomoto T, Iwasaki Y, Otani Y, Tsuchiya S . Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer. 2004; 46(3):305-12. DOI: 10.1016/j.lungcan.2004.05.003. View

Li W, Deng J, Wang S, Ma L, Pei J, Zeng X . Association of methylation of the RAR-β gene with cigarette smoking in non-small cell lung cancer with Southern-Central Chinese population. Asian Pac J Cancer Prev. 2015; 15(24):10937-41. DOI: 10.7314/apjcp.2014.15.24.10937. View

Arrieta O, Alba E, Alba-Lopez L, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza J . [National consensus of diagnosis and treatment of non-small cell lung cancer]. Rev Invest Clin. 2014; 65 Suppl 1:S5-84. View

Nicholson S, Whitehouse H, Naidoo K, Byers R . Yin Yang 1 in human cancer. Crit Rev Oncog. 2012; 16(3-4):245-60. DOI: 10.1615/critrevoncog.v16.i3-4.80. View

Chakravarti N, Lotan R, Diwan A, Warneke C, Johnson M, Prieto V . Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin Cancer Res. 2007; 13(16):4817-24. DOI: 10.1158/1078-0432.CCR-06-3026. View

Wongtrakool C, Malpel S, Gorenstein J, Sedita J, Ramirez M, Underhill T . Down-regulation of retinoic acid receptor alpha signaling is required for sacculation and type I cell formation in the developing lung. J Biol Chem. 2003; 278(47):46911-8. PMC: 2168590. DOI: 10.1074/jbc.M307977200. View

William Jr W, Lin H, Lee J, Lippman S, Roth J, Kim E . Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009; 136(3):701-709. DOI: 10.1378/chest.08-2968. View

Scagliotti G, de Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S . Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20(21):4285-91. DOI: 10.1200/JCO.2002.02.068. View

10.

Inui N, Sasaki S, Suda T, Chida K, Nakamura H . The loss of retinoic acid receptor alpha, beta and alcohol dehydrogenase3 expression in non-small cell lung cancer. Respirology. 2003; 8(3):302-9. DOI: 10.1046/j.1440-1843.2003.00481.x. View

11.

Desai T, Chen F, Lu J, Qian J, Niederreither K, Dolle P . Distinct roles for retinoic acid receptors alpha and beta in early lung morphogenesis. Dev Biol. 2006; 291(1):12-24. DOI: 10.1016/j.ydbio.2005.10.045. View

12.

Arrieta O, Hernandez-Pedro N, Fernandez-Gonzalez-Aragon M, Saavedra-Perez D, Campos-Parra A, Rios-Trejo M . Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology. 2011; 77(10):987-95. PMC: 3171957. DOI: 10.1212/WNL.0b013e31822e045c. View

13.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

14.

Zornosa C, Vandergrift J, Kalemkerian G, Ettinger D, Rabin M, Reid M . First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc Netw. 2012; 10(7):847-56. DOI: 10.6004/jnccn.2012.0088. View

15.

Arrieta O, Ramirez-Tirado L, Baez-Saldana R, Pena-Curiel O, Soca-Chafre G, Macedo-Perez E . Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox". Lung Cancer. 2015; 90(2):161-6. DOI: 10.1016/j.lungcan.2015.08.010. View

16.

Cetin K, Ettinger D, Hei Y, OMalley C . Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol. 2011; 3:139-48. PMC: 3096514. DOI: 10.2147/CLEP.S17191. View

17.

Blumenschein Jr G, Khuri F, von Pawel J, Gatzemeier U, Miller Jr W, Jotte R . Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol. 2008; 26(11):1879-85. DOI: 10.1200/JCO.2007.12.2689. View

18.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

19.

Larsson L, Henriksson M . The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res. 2010; 316(8):1429-37. DOI: 10.1016/j.yexcr.2010.03.025. View

20.

Khuri F, Lotan R, Kemp B, Lippman S, Wu H, Feng L . Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol. 2000; 18(15):2798-804. DOI: 10.1200/JCO.2000.18.15.2798. View